Xiong Ying, Shi Liang-Liang, Zhu Li-Sheng, Peng Gang
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ann Palliat Med. 2021 Apr;10(4):4122-4133. doi: 10.21037/apm-20-2033. Epub 2021 Mar 23.
To evaluate the prognostic value of pretreatment prognostic nutritional index (PNI), lactated dehydrogenase (LDH) and their combination (PNI-LDH) in patients with locally advanced NPC receiving induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT).
A total of 213 patients diagnosed with locally advanced (III-IVA) NPC between January 2013 and December 2017 were retrospectively reviewed. The optimal PNI and LDH cutoff values were determined by the quartiles. The association between PNI and LDH and the clinicopathological characteristics of the patients was examined. Survival curves were analyzed using the Kaplan-Meier method and compared by the log-rank test between the different PNI and LDH subgroups. Univariate and multivariate analyses were performed by the Cox proportional hazards regression model to evaluate the prognostic impact on overall survival (OS), progression-free survival (PFS), locoregional recurrence free survival (LRFS) and distant metastasis-free survival (DMFS). Furthermore, the prognostic values of the PNI, LDH, and PNI-LDH were evaluated by comparing the AUC area.
The optimal cut-off values of PNI and LDH were 52 and 177, respectively. Multivariate analyses revealed that patients with a higher PNI had inferior OS (P=0.027), PFS (P=0.040), LRFS (P=0.015) and DMFS (P=0.040), and patients with a higher LDH level had poorer OS (P=0.040), PFS (P=0.001), LRFS (P=0.001) and DMFS (P=0.001). Furthermore, EBV DNA positive, stage IVA were independent prognostic factors for survival outcomes in the multivariate analyses. Moreover, we further demonstrated that low PNI-high LDH in locally advanced NPC patients was significantly related to poor OS (P=0.012), PFS (P=0.001), LRFS (P=0.001) and DMFS (P=0.001). The AUC of the PNI, LDH and PNI-LDH were 0.653 (P=0.021), 0.647 (P=0.028) and 0.751 (P=0.001), respectively, indicating that PNI-LDH is superior to either score alone.
Pretreatment PNI and LDH could be considered as valuable predictors for survival outcomes in locally advanced NPC patients. The combination of them, superior to either score alone, can be used as a supplement to the traditional TNM staging system.
评估预处理预后营养指数(PNI)、乳酸脱氢酶(LDH)及其联合指标(PNI-LDH)对局部晚期鼻咽癌患者诱导化疗(IC)后序贯同步放化疗(CCRT)的预后价值。
回顾性分析2013年1月至2017年12月期间诊断为局部晚期(III-IVA期)鼻咽癌的213例患者。通过四分位数确定最佳PNI和LDH临界值。研究PNI和LDH与患者临床病理特征之间的关联。采用Kaplan-Meier法分析生存曲线,并通过对数秩检验比较不同PNI和LDH亚组之间的差异。采用Cox比例风险回归模型进行单因素和多因素分析,以评估对总生存(OS)、无进展生存(PFS)、局部区域无复发生存(LRFS)和远处转移无复发生存(DMFS)的预后影响。此外,通过比较AUC面积评估PNI、LDH和PNI-LDH的预后价值。
PNI和LDH的最佳临界值分别为52和177。多因素分析显示,PNI较高的患者OS(P=0.027)、PFS(P=0.040)、LRFS(P=0.015)和DMFS(P=0.040)较差,LDH水平较高的患者OS(P=0.040)、PFS(P=0.001)、LRFS(P=0.001)和DMFS(P=0.001)较差。此外,在多因素分析中,EBV DNA阳性、IVA期是生存结局的独立预后因素。而且,我们进一步证明局部晚期鼻咽癌患者低PNI-高LDH与较差的OS(P=0.012)、PFS(P=0.001)、LRFS(P=0.001)和DMFS(P=0.001)显著相关。PNI、LDH和PNI-LDH的AUC分别为0.653(P=0.021)、0.647(P=0.028)和0.751(P=0.001),表明PNI-LDH优于单独的任何一个指标。
预处理PNI和LDH可被视为局部晚期鼻咽癌患者生存结局的有价值预测指标。它们的联合指标优于单独的任何一个指标,可作为传统TNM分期系统的补充。